Le Lézard
Classified in: Health

Virginia Urology Announces Dr. Kinloch Nelson's Designation as UroLift® Center of Excellence


MECHANICSVILLE, Va., April 19, 2018 /PRNewswire-PRWeb/ -- Virginia Urology today announced Dr. Kinloch Nelson has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Nelson has achieved a high level of training and experience with the UroLift System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia or BPH.

"The UroLift System is the only BPH treatment available that is truly minimally-invasive," said Dr. Nelson. "It can be performed at the ambulatory surgery center without heating, cutting or removal of prostate tissue. Patients are able to get back to their normal routines quickly and can discontinue the use of medications. It is a privilege to offer my patients a breakthrough treatment option that offers real long-term results."

Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Five-year data from a randomized study shows the UroLift System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.

To schedule a consultation with Dr. Nelson, please call 804-330-9105.

About the UroLift System
NeoTract's FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About Virginia Urology
Virginia Urology (VU) has a long history of providing quality care to the Greater Richmond metro area for over 75 years. This practice prides itself on its strong commitment to the community's urological needs by recruiting highly skilled physicians and using the latest technology. The practice is comprised of over 40 physicians that include urologists & urogynecologists as well as physicians specializing in the urologic aspect of anesthesiology, pathology, radiation oncology, and radiology. Because we have such diverse medical professionals we are able to provide the latest technologies with our mission of providing the best possible care for each patient. Our board-certified physicians and staff are dedicated to offering care that blends state-of-the-art medical expertise with compassionate, individualized attention. The group has urology specialists spanning nearly every discipline within the field of urology. Learn more at http://www.uro.com    

Media Contact:
Amy Cramer
Amy(at)healthandcommerce(dot)com
M: 650-391-3714

 

SOURCE Virginia Urology


These press releases may also interest you

at 17:56
The Canadian Cancer Society commends the increases in taxes on tobacco and e-cigarettes in today's federal budget.  The budget increases tobacco taxes by $4.00 per carton of 200 cigarettes effective at midnight, and increases e-cigarette taxes by 12%...

at 17:45
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to...

at 17:31
The rise in demand for dental lasers is mainly driven by the growing occurrence of dental issues like bleeding or inflamed gums, tooth decay, and root infections. Furthermore, advancements in dental technology play a significant role in fostering...

at 17:26
Amgen today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American...

at 17:05
Antibe Therapeutics Inc. ("Antibe" or the "Company") announced that the Toronto Stock Exchange ("TSX") is reviewing the eligibility for continued listing on the TSX of the securities of the Company. The TSX has identified the Company's financial...

at 16:30
Viatris Inc.  will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the...



News published on and distributed by: